Sanford C. Bernstein Upgrades Revvity (NYSE:RVTY) to “Hold”

Revvity (NYSE:RVTY) was upgraded by stock analysts at Sanford C. Bernstein to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other research analysts also recently issued reports on the company. The Goldman Sachs Group dropped their price objective on Revvity from $110.00 to $95.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 14th. JPMorgan Chase & Co. lowered their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Wolfe Research began coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. TD Cowen increased their price target on Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Stifel Nicolaus reduced their price objective on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $108.33.

Revvity Price Performance

Shares of NYSE RVTY opened at $112.98 on Thursday. Revvity has a twelve month low of $81.22 and a twelve month high of $118.30. The firm has a fifty day simple moving average of $97.46 and a 200 day simple moving average of $97.75. The company has a market capitalization of $12.60 billion, a PE ratio of 54.06, a P/E/G ratio of 2.48 and a beta of 1.11. The company has a quick ratio of 1.41, a current ratio of 1.72 and a debt-to-equity ratio of 0.37.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The business had revenue of $711.12 million for the quarter, compared to analyst estimates of $704.07 million. During the same quarter in the previous year, the business earned $1.01 earnings per share. Revvity’s revenue for the quarter was up 7.0% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, sell-side analysts forecast that Revvity will post 5.25 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. EdgePoint Investment Group Inc. lifted its position in Revvity by 3.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after acquiring an additional 265,204 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Revvity by 5.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after purchasing an additional 434,570 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock valued at $731,386,000 after purchasing an additional 186,956 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Revvity by 11.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,917,953 shares of the company’s stock valued at $255,623,000 after purchasing an additional 305,837 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Revvity by 29.6% during the fourth quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after buying an additional 650,083 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.